Immatics N.V. (NASDAQ:IMTX) Given Average Rating of “Moderate Buy” by Brokerages

Immatics N.V. (NASDAQ:IMTX) has been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $20.80.

Several analysts recently commented on IMTX shares. Weiss Ratings cut Immatics from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, June 23rd. Chardan Capital restated a “buy” rating and issued a $25.00 price target on shares of Immatics in a research report on Tuesday, May 19th. Wall Street Zen lowered shares of Immatics from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Jefferies Financial Group started coverage on shares of Immatics in a research note on Monday, March 16th. They issued a “buy” rating and a $18.00 price objective on the stock. Finally, TD Cowen started coverage on shares of Immatics in a research note on Tuesday, April 28th. They set a “buy” rating for the company.

Institutional Trading of Immatics

Large investors have recently bought and sold shares of the business. Vanguard Personalized Indexing Management LLC lifted its stake in shares of Immatics by 3.7% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 49,374 shares of the company’s stock valued at $518,000 after purchasing an additional 1,739 shares during the period. Bank of America Corp DE boosted its position in shares of Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after purchasing an additional 2,231 shares in the last quarter. Barclays PLC grew its stake in Immatics by 11.4% during the fourth quarter. Barclays PLC now owns 28,185 shares of the company’s stock worth $296,000 after purchasing an additional 2,874 shares during the period. Virtus Investment Advisers LLC grew its stake in Immatics by 43.0% during the fourth quarter. Virtus Investment Advisers LLC now owns 26,497 shares of the company’s stock worth $278,000 after purchasing an additional 7,965 shares during the period. Finally, Quarry LP acquired a new stake in Immatics during the fourth quarter worth approximately $84,000. 64.41% of the stock is currently owned by institutional investors and hedge funds.

Immatics Stock Down 2.7%

Shares of NASDAQ:IMTX opened at $9.98 on Thursday. The firm has a market cap of $1.34 billion, a P/E ratio of -5.02 and a beta of 1.32. Immatics has a 12-month low of $5.05 and a 12-month high of $12.41. The business has a fifty day simple moving average of $10.40 and a 200 day simple moving average of $10.18.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.08). Immatics had a negative net margin of 572.35% and a negative return on equity of 47.36%. The company had revenue of $8.81 million during the quarter, compared to analyst estimates of $9.79 million. As a group, equities research analysts expect that Immatics will post -1.67 EPS for the current year.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.